HGCC
Human Glioma Cell Cultures.
HGCC is a biobanking effort to provide a panel of newly established and characterized GBM cell lines from GBM patient surgical samples, currently holding 48 cell lines. The HGCC cell lines and accompanying data are available as an open resource facilitating accurate modeling of GBM diversity for basic research and drug discovery.

|
|
|
|
HGCC Biobank

Glioblastoma and GSCs
From patient to treatment.
The concept of glioma stem cells (GSCs) has attracted a lot of interest, and a glioma-initiating cell bearing stem cell characteristics has been proposed, with the ability to seed new tumors through the capacity to evade chemotherapy and irradiation.
Basic cancer research, including preclinical tumor models and testing of candidate drugs needs optimized in vitro models that better reflect the patient’s disease, including modeling of the cancer stem cell compartment. We have set up a biobanking effort to culture and characterize a new panel of cells, derived from GBM patient biopsies, based on a combination of two validated techniques for culturing GSCs (Xie et al. 2015). Here, we report the establishment, genomic characterization and in vivo validation of 48 patient-derived GBM cell lines cultured under stem cell conditions, and that they represent all four molecular GBM subtypes.
Patient Material
Diagnosis | Number of patients | Mean age (span) | Male | Female | Number of cell lines | Cell line rate (%) |
---|---|---|---|---|---|---|
All glioma | 101 | 60.7 (21-82) | 56 | 45 | 54 | 47.4 |
Grade IV | 83 | 53 | 55.8 | |||
Glioblastoma | 82 | 62.5 (21-82) | 47 | 35 | 53 | 56.4 |
Gliosarcoma | 1 | 78 | 1 | 0 | 0.0 | |
Grade III | 13 | 1 | 7.7 | |||
Anaplastic astrocytoma | 4 | 45.8(29-63) | 0 | 4 | 1 | 25 |
Anaplastic oligodendroglioma | 9 | 52.6(26-73) | 4 | 5 | 0 | 0 |
Grade II | 5 | 0 | 0 | |||
Oligodendroglioma | 4 | 55.3(42-68) | 3 | 1 | 0 | 0 |
Pleomorphic xanthoastrcytoma | 1 | 57 | 1 | 0 | 0 | 0 |
HGCC in Action
Drug Development and Characterization.
A number of studies have been published using HGCC. Here we summarize the cell lines used in each study.
U3002 | U3004 | U3005 | U3008 | U3009 | U3013 | U3016 | U3017 | U3019 | U3020 | U3021 | U3024 | U3027 | U3028 | U3029 | U3031 | U3033 | U3034 | U3035 | U3037 | U3039 | U3042 | U3046 | U3047 | U3048 | U3051 | U3053 | U3054 | U3056 | U3060 | U3062 | U3065 | U3067 | U3068 | U3071 | U3073 | U3078 | U3082 | U3084 | U3085 | U3086 | U3088 | U3101 | U3110 | U3117 | U3118 | U3121 | U3123 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Xie et al. | ||||||||||||||||||||||||||||||||||||||||||||||||
Wee et al. | ||||||||||||||||||||||||||||||||||||||||||||||||
Babateen et al. | ||||||||||||||||||||||||||||||||||||||||||||||||
Savary et al. | ||||||||||||||||||||||||||||||||||||||||||||||||
Yu et al. | ||||||||||||||||||||||||||||||||||||||||||||||||
Kundu et al. | ||||||||||||||||||||||||||||||||||||||||||||||||
Wee et al. | ||||||||||||||||||||||||||||||||||||||||||||||||
Truve et al. | ||||||||||||||||||||||||||||||||||||||||||||||||
Roy et al. | ||||||||||||||||||||||||||||||||||||||||||||||||
Schmidt et al. | ||||||||||||||||||||||||||||||||||||||||||||||||
Segerman et al. | ||||||||||||||||||||||||||||||||||||||||||||||||
Jiang et al. | ||||||||||||||||||||||||||||||||||||||||||||||||
Pinheiro et al. | ||||||||||||||||||||||||||||||||||||||||||||||||
Pudelko et al. |
Supported By



References
EBioMedicine 2015 Aug 15;2(10):1351-63.
U3002, U3004, U3005, U3008, U3009, U3013, U3016, U3017, U3019, U3020, U3021, U3024, U3027, U3028, U3029, U3031, U3033, U3034, U3035, U3037, U3039, U3042, U3046, U3047, U3048, U3051, U3053, U3054, U3056, U3060, U3062, U3065, U3067, U3068, U3071, U3073, U3078, U3082, U3084, U3085, U3086, U3088, U3101, U3110, U3117, U3118, U3121, U3123
PLoS One. 2014 Dec 22;9(12):e115698.
U3047, U3013, U3065, U3037, U3035, U3024, U3084, U3046, U3017
Eur J Pharmacol. 2014 Dec 12;748C:101-107.
U3047
Oncogene. 2013 Nov 21;32(47):5409-20.
U3028, U3034
PLoS One. 2013;8(1):e54952. Epub 2013 Jan 25.
U3013, U3054
Mol Cancer Res. 2016 Dec;14(12):1243-1253.
U3013, U3024
Sci Rep. 2016 Jul 26;6:25956.
U3020
PLoS Genet. 2016 May;12(5):e1006000.
U3004, U3009, U3013, U3021, U3029, U3031, U3054
Oncotarget. 2015 Sep 15;6(27):23647-61.
U3016, U3047, U3117, U3065, U3060, U3062, U3101
Oncotarget 2016 Nov 8;7(45):73200-73215.
U3013, U3017, U3024, U3037, U3065, U3084, U3002, U3004, U3005, U3009, U3020, U3035, U3008, U3016, U3021, U3027, U3031, U3046, U3029, U3028, U3033, U3039, U3047, U3085, U3019, U3034, U3056, U3082, U3086, U3117, U3053, U3054, U3060, U3073, U3078, U3088, U3051, U3062, U3068, U3110, U3118, U3129
Cell Reports 2016 Dec 13;17(11):2994-3009.
U3017, U3065, U3117, U3118, U3121, U3167
Cell Reports 2017 Jan 24;18(4):977-990.
U3002, U3005, U3008, U3009, U3013, U3017, U3020, U3021, U3024, U3027, U3028, U3029, U3031, U3033, U3034, U3035, U3037, U3039, U3042, U3046, U3047, U3048, U3051, U3053, U3056, U3060, U3062, U3065, U3068, U3071, U3073, U3078, U3082, U3084, U3085, U3086, U3088, U3093, U3101, U3102, U3104, U3110, U3117, U3118, U3121, U3123, U3129, U3137, U3140, U3146, U3155, U3164, U3167, U3169, U3172, U3173, U3175, U3180, U3189, U3198, U3202
Biochem Biophys Res Commun. 2017 Dec 16;494(3-4):477-483.
U3005, U3028, U3046
Neuro Oncol 2018 May 10. doi: 10.1093/neuonc/noy071
U3024, U3101
Image Attributions
Glioblastoma MRI, Case courtesy of Dr Frank Gaillard, Radiopaedia.org. From the case Glioblastoma multiforme (GBM) with PNET componentStart page background: Intermediate magnification micrograph of a glioblastoma
Copyright © 2011 Nephron
Permission is granted to copy, distribute and/or modify this image under the terms of the GNU Free Documentation License Version 1.2 or any later version published by the Free Software Foundation.